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Abbreviations 
AA   Arachidonic acid 
ALA   α-Linolenic acid 
ANGPTL4  Angiopoietin-like 4 
AP-1   Activator protein 1 
APC   Antigen presenting cell 
CD   Cluster of differentiation 
ChIP   Chromatin immunoprecipitation 
DC   Dendridic cell 
DHA   Docosahexaenoic acid 
EGF   Epidermal growth factor 
EPA   Eicosapentaenoic acid 
FA   Fatty acid 
FCS   Fetal calf serum 
INF-γ   Interferon γ 
IL   Interleukin 
IPA   Ingenuity Pathway Analysis 
LA   Linoleic acid 
LBD   Ligand binding domain 
LC-MS/MS  Liquid chromatography–mass spectrometry/mass spectrometry 
LPS   Lipopolysaccharide 
MDM   Monocyte-derived macrophages 
MMP   Matrix-metalloproteinase 
mRNA   Messenger ribonucleic acid 
NF-κB   nuclear factor kappa-light-chain-enhancer of activated B cells 
PAMP   Pathogen-associated-molecular-pattern 
PDK4   Pyruvate dehydrogenase kinase 4 
PPAR   Peroxisome proliferator-activated receptor 
PRR   Pattern recognition receptor 
PPRE   PPAR response element 
PUFA   Polyunsaturated fatty acid 
RT-qPCR  Reverse transcription quantitative polymerase chain reaction 
RXR   Retinoid X receptor 
STAT   Signal transducer and activator of transcription 
TAM   Tumor-associated macrophage 
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TZD   Thiazolidindion 
VEGF   Vascular endothelial growth factor 
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1 Summary 
Macrophages represent the most diverse cell type in biology. They adapt selectively to 
many stimuli allowing for precise functionality in any environment without harming the 
organism. Consequently, they monitor their surroundings carefully and react to a 
plethora of signals. Fatty acids and their derivatives are important signaling mediators 
in this context, which besides other signals impinge on the lipid-regulated nuclear 
receptor peroxisome proliferator-activated receptor (PPARβ/δ). 
Studies conducted in mice have shown that ablation of PPARβ/δ results in the 
inability of adipose and liver macrophages to adopt an alternative anti-inflammatory 
activation state, demonstrating a prominent role of PPARβ/δ in macrophage function 
with implications for immune regulation. To date, however, systematic studies focusing 
on PPARβ/δ's role in human macrophages have not been reported. 
The first part of this thesis addresses the role of PPARβ/δ in human 
macrophages including its transcriptional network affecting a multitude of cellular 
processes. A major part of this network involves cell type independent canonical 
regulation, which is characterized by the binding of PPARβ/δ with its obligatory 
dimerization partner retinoid X receptor (RXR) to specific sites in the regulatory region 
of established and previously unreported target genes, their induction by agonists and 
repression by inverse agonists. Additionally, a new set of non-canonical regulated 
target genes is described. These genes lack chromatin-bound PPARβ/δ complexes, 
are repressed by agonists (inverse regulation) and are macrophage-selective. 
Consistent with the prevailing opinion and the induction of an IL4-like morphological 
phenotype by agonists, this mode of regulation inhibits pro-inflammatory signaling. 
Surprisingly, anti-inflammatory genes, such as CD32B, IDO1 and CD274 (PD-L1) were 
also repressed. Consistent with these results, immune functions such as CD8+ T cell 
activation were stimulated by these ligands. In combination, these findings point to a 
unique macrophage activation state induced by PPARβ/δ agonists with context 
dependent functions in immune regulation. 
The second part describes the PPARβ/δ-regulated transcriptome for tumor-
associated macrophages (TAMs) from human serous ovarian carcinoma ascites. 
Interestingly, most canonical PPARβ/δ target genes were found to be upregulated and 
refractory to synthetic agonists as compared to monocyte-derived macrophages. This 
was not due to a TAM specific increase in PPARβ/δ protein level or recruitment to 
target genes. However, the unaffected response of these genes to inverse agonists 
hinted at the presence of endogenous activating ligands. Lipidomic analysis of 
Summary 
 
5 
 
malignancy-associated ascites indeed revealed very high concentrations of dietary 
polyunsaturated fatty acids (PUFAs), mainly linoleic and arachidonic acid. These 
PUFAs induced lipid droplet formation in macrophages which provide a potential 
reservoir for PPARβ/δ agonists and may serve as the causal nexus for target gene 
deregulation. Among the deregulated genes, ANGPTL4 is associated with shorter 
relapse-free survival, illustrating the potential clinical implications of these findings. 
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Zusammenfassung 
Makrophagen stellen den divergentesten Zelltyp dar. Sie beeinflussen und modellieren 
ihre Umgebung auf vielfältige Weise. Folglich müssen diese Zellen die auf sie 
wirkenden Umwelteinflüsse wahrnehmen und verarbeiten, um eine adäquate 
Adaptation zu gewährleisten. Nur so kann eine Schädigung des Organismus bei 
gleichzeitigem Erhalt der Funktionalität ausgeschlossen werden. Ein in diesem Kontext 
wichtiger Faktor ist die Verfügbarkeit und Zusammensetzung von Fettsäuren und ihren 
Derivaten, welche nebst anderen Signalen, auf den lipidregulierten Kernrezeptor 
Peroxisome Proliferator-Activated Receptor (PPARβ/δ) einwirken. 
Versuche in Mäusen haben gezeigt, dass dessen genetische Ablation dazu führt, 
dass Fettgewebs- und Leber- Makrophagen nicht mehr befähigt sind einen alternativen 
anti-inflammatorischen Aktivierungszustand einzunehmen. Diese Ergebnisse 
unterstreichen die wichtige Rolle von PPARβ/δ in Makrophagen und der 
Immunregulation. Dennoch liegen bis heute keine systematischen Studien, die sich auf 
die Rolle von PPARβ/δ in humanen Makrophagen fokussieren, vor. 
Die vorliegende Arbeit beschreibt die Rolle von PPARβ/δ in humanen 
Makrophagen inklusive seines transkriptionellen Netzwerks, das auf eine Vielzahl 
zellulärer Prozesse einwirkt. Zum einen wird dies durch die zelltypunabhängige 
kanonische Regulation bewirkt. Dabei bindet PPARβ/δ mit seinem obligatorischen 
Dimerisierungspartner Retenoid X Receptor (RXR) direkt an spezielle Stellen in den 
regulatorischen Regionen bereits bekannter und neubeschriebener spezifischer 
Zielgene, wodurch die Transkription durch Agonisten induziert und durch inverse 
Agonisten reprimiert wird. Zum anderen wird eine neue Klasse von nicht-kanonisch 
regulierten Zielgenen beschrieben. Diese Gene weisen keine chromatinassozierten 
PPARβ/δ Komplexe auf, werden durch Agonisten reprimiert und sind makrophagen-
selektiv (inverse Regulation). Im Einklang mit der vorherrschenden Ansicht und der 
Induktion eines IL4-ähnlichen morphologischen Phänotyps durch Agonisten, inhibiert 
diese Art der Regulation pro-inflammatorische Funktionen. Überraschenderweise 
werden jedoch gleichzeitig auch anti-inflammatorische Gene, unter anderen CD32B, 
IDO1 und CD274 (PD-L1) reprimiert. Entsprechend konnte eine makrophagen-
abhängige Stimulation der CD8+ T-Zell Aktivierung durch diese Liganden beobachtet 
werden. In Kombination deuten diese Beobachtungen auf eine besondere Rolle von 
PPARβ/δ mit kontextabhängiger Funktion in der Immunregulation hin. 
Der zweite Teil beschreibt das durch PPARβ/δ regulierte Transkriptom tumor-
assoziierter Makrophagen (TAMs) aus dem Aszites von Patientinnen mit serösem 
Ovarialkarzinom. Beachtenswerterweise ist im Vergleich zu monozyten-abgeleiteten 
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Makrophagen die Mehrheit der PPARβ/δ Zielgene überexprimiert und refraktär 
gegenüber Agonisten, was weder auf ein erhöhtes Proteinlevel noch die vermehrte 
Rekrutierung an Zielgene zurückzuführen ist. Der Einfluss von inversen Agonisten auf 
TAMs war gleichzeitig unverändert, was auf die Gegenwart von endogenen 
aktivierenden Liganden hindeutete. Analysen von Aszitesproben hinsichtlich der 
Lipidzusammensetzung offenbarten tatsächlich stark erhöhte Konzentrationen 
mehrfachungesättigter Fettsäuren, vor allem Linolsäure und Arachidonsäure. Diese 
Fettsäuren verursachten die Bildung von Lipidtröpfchen in Makrophagen, welche 
ihrerseits ein potentielles Reservoir für PPARβ/δ Agonisten darstellen könnten, was 
wiederum eine Erklärung für die Deregulierung von PPARβ/δ Zielgenen bietet. Unter 
den deregulierten Genen findet sich ANGPTL4, dessen erhöhte Expression mit einem 
verkürzten rezidivfreien Überleben assoziiert ist und somit die potentielle klinische 
Bedeutung dieser Beobachtungen unterstreicht. 
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2 Introduction 
2.1 Peroxisome Proliferator-Activated Receptors (PPARs) 
Peroxisome proliferator-activated receptors were named after their potential to bind 
peroxisome proliferators (Issemann & Green 1990), a diverse group of chemical 
substances that increase size and number of peroxisomes in rodents. Peroxisomes are 
organelles especially associated with fatty acid α and β oxidation although exerting 
other functions such as the biosynthesis of ether phospholipids or the reduction of 
hydrogen peroxide (Wanders & Waterham 2006). These ligand-regulated transcription 
factors are members of the nuclear receptor superfamily. In mammals three types of 
PPARs with diverse tissue distribution have been characterized PPARα, PPARβ/δ and 
PPARγ (Dreyer et al. 1992; Braissant et al. 1996). All three subtypes are in vivo 
sensors and transcriptional effectors of dietary fatty acids and their derivatives (Forman 
et al. 1997). They act through the control of specific gene subsets which strongly 
influence metabolic functions, making these modulators intriguing pharmacologic 
targets. 
2.1.1 PPAR subtypes: a short overview 
The alpha isoform is predominantly expressed in tissue involved in lipid catabolism 
such as liver, brown fat, heart and intestine (Braissant et al. 1996; Rakhshandehroo et 
al. 2010), where its major role is regulation of lipid metabolism and energy 
homeostasis. Fibrates, synthetic ligands specifically activating PPARα, are therefore 
used to treat hypercholesterolemia since the 1930s. 
PPARβ/δ is ubiquitously expressed and associated with a wide range of 
functions. It is involved in regulating intermediary metabolism (Desvergne et al. 2006), 
especially fatty acid oxidation, showing overlap with PPARα, but also glucose 
homeostasis (Muoio et al. 2002; Lee et al. 2006). Moreover PPARβ/δ has been 
reported to exert important roles in differentiation, wound healing, tumorigenesis and 
modulation of cell proliferation and immune function (Peters et al. 2000; Michalik et al. 
2001; Müller-Brüsselbach et al. 2007; Müller, Rieck, et al. 2008; Müller, Kömhoff, et al. 
2008; Kilgore & Billin 2008; Peters et al. 2015). Nonetheless these reports are due to in 
part deviating murine models. Efforts to study PPARβ/δ in the light of pathophysiology 
and immunology have been perpetuated particularly through the advent of selective 
ligands (Oliver Jr. et al. 2001; Sznaidman et al. 2003). These ligands permit modulation 
of PPARβ/δ specific transcription with potential for clarifying its role in biological 
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systems on one side and investigating the role as potential therapeutic target on the 
other. In fact the potential for GW501516, a specific PPARβ/δ agonist, in treating 
dyslipidemia has been evaluated in two phase-two studies. 
PPARγ is found mainly in adipose tissue. Through alternative transcription start 
sites and splicing PPARγ has two distinct isoforms in man: PPARγ2 and the 
predominantly expressed PPARγ1. PPARγ1 is found in a variety of tissues including 
immune cells while the PPARγ2 isoform is restricted to adipose tissue (Fajas et al. 
1997). PPARγ is eminently important for adipogenesis, shown by the fact that forced 
expression of PPARγ in fibroblasts leads to terminal adipocyte differentiation (Rosen et 
al. 1999; Rosen et al. 2000; Tontonoz et al. 1994). On the other hand, mice deficient in 
PPARγ expression fail to generate adipose tissue, even if fed a high fat diet (Jones et 
al. 2005). Thiazolidinedione (TZD) was revealed to be a highly specific agonistic ligand 
for PPARγ causing increased lipid storage into adipocytes (Lehmann et al. 1995). The 
reduction of free fatty acids in circulation in combination with altered adipose-derived 
endocrine factors results in reduced systemic insulin resistance, which is favorable for 
the treatment of diabetes mellitus type 2 (Evans 2004; Rangwala & Lazar 2004). In fact 
Troglitazone was found to improve insulin resistance and used to treat type 2 diabetes 
prior to the discovery of its mode of action through PPARγ in 1995 (Fujiwara et al. 
1988; Suter et al. 1992; Nolan et al. 1994). Today, however, TZDs prescription to treat 
insulin resistance is no longer advised due to various side effects. As of 2011, 
Pioglitazone remains the only approved TZD on the European market, although being 
associated with increased risk for bladder cancer (Ferwana et al. 2013). 
2.1.2 PPAR structure 
PPARs are members of the nuclear receptor family and are thus composed of the 
same structurally definable domains all nuclear receptors share (Laudet et al. 1992; 
Kumar & Thompson 1999). At the N-terminus of the protein, there is a highly various 
domain that contains an activation function known to be ligand independent (Wärnmark 
et al. 2003). Secondly, a DNA binding domain containing two zinc-finger motifs is 
present. This domain binds the hormone response elements specific for each receptor. 
The third structure module is a flexible hinge, which is followed by the C-terminal ligand 
binding domain (LBD). This alpha helical domain consists of twelve helices and a four-
stranded β-sheet forming not only the binding pocket for the ligand but contributing also 
to the dimerization and co-factor binding ability (Xu et al. 1999; Zoete et al. 2007; 
Schwarz et al. 2016). Moreover it harbors the ligand dependent second activation 
function, most important for full transcriptional activation (Wärnmark et al. 2003). 
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2.1.3 PPAR transcriptional activity and ligand control 
PPAR transcriptional activity is regulated by ligands and depends on obligate 
heterodimerization with retinoid X receptor (Nolte et al. 1998). These heterodimers bind 
to PPAR response elements (PPRE) in the promoter region of PPAR target genes. 
PPAR response elements are composed of direct repeats with the consensus 
sequence AGGTCA, spaced by one base pair (Leid et al. 1992; Adhikary et al. 2011). 
In the absence of ligand, PPARs recruit co-repressor complexes. Upon binding of an 
agonistic ligand the co-repressor complex is dismissed and co-activator complexes, 
leading to histone hyperacetylation and subsequent transcriptional activation, are 
recruited (Guan et al. 2005). 
Specific ligands that fit the binding pocket of the LBD influence the 
transcriptional activity markedly. The amino acid residues comprising the surface of the 
ligand-binding pocket located in the LBD are 80% conserved between the three 
subtypes (Zoete et al. 2007). The remaining residues mediate ligand selectivity, 
although this pocket is by far the largest among nuclear receptors. The reason for this 
apparent paradox can be explained by the “mouse trap” model proposed as early as 
1995 (Renaud et al. 1995). In this model, the binding of a specific ligand results in 
conformational changes of the LBD. In sum, this leads to a compacted structure where 
the highly motile helix twelve forms a lid contributing to the binding pocket surface. 
Consequently, this induced fit enhances the ligand enclosure and creates stable 
binding sites on the exterior necessary for full activation. Inverse agonists on the other 
hand, recruit co-repressors resulting in repressed transcriptional activity. 
2.1.4 PPARs in the context of immune regulation 
All PPAR subtypes have been implicated to play a role in immune regulation (Daynes & 
Jones 2002). The first report describing this link revealed leukotriene B4 to be a 
PPARα activating ligand controlling the duration of the inflammatory response 
(Devchand et al. 1996). Following this first publication, a number of reports found anti-
inflammatory properties for PPARα mainly in murine models (Straus & Glass 2007; 
Bensinger & Tontonoz 2008). Since then, activation of both PPARα and PPARγ have 
been shown to limit pro-inflammatory cytokine production in T-cells and induce 
apoptosis in human macrophages (Chinetti et al. 1998; Marx et al. 2002).  
PPARγ has since become the best studied subtype in the context of immune 
regulation. Its part in macrophage and dendritic cell (DC) function has been studied 
extensively (Nencioni et al. 2002; Szatmari et al. 2006). Activating ligands inhibit DC 
maturation as well as pro-inflamatory cytokine and chemokine production by these 
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cells. In combination, these effects lead to reduced antigen presentation and thereby 
impaired T-cell activation (Klotz et al. 2007). Adding to the complexity mechanisms by 
which cytokines affect the myeloid cell function via PPARγ have also been reported 
(Szanto et al. 2010; Schneider et al. 2014). 
To date, knowledge about the precise role of PPARβ/δ in immune regulation is 
scarce. Studies, mostly in murine models, have however emphasized an involvement 
in inflammation and wound healing (Michalik et al. 2001; Tan et al. 2001; Lee et al. 
2003; Welch et al. 2003; Tan et al. 2004). PPARβ/δ was soon linked to a role in 
macrophage function where it modulates a multitude of inflammatory pathways e.g. 
activator protein 1 (AP-1), nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) and signal transducers and activators of transcription (STATs) (Barish et 
al. 2008; Zingarelli et al. 2010). Other studies showed the potential of PPARβ/δ specific 
agonistic ligands to dampen T-cell-mediated experimental autoimmune 
encephalomyelitis by blocking interleukin 17 and interferon γ (IFN-γ) production 
(Kanakasabai et al. 2010; Dunn et al. 2010). Ablation of PPARβ/δ underlined its 
importance for development of an alternatively activated macrophage phenotype and 
led, for instance, to a reduced production of anti-inflammatory cytokines (Gallardo-
Soler et al. 2008; Kang et al. 2008; Odegaard et al. 2008; Mukundan et al. 2009). The 
anti-inflammatory effect of the pan-PPAR agonist punicic acid, for example, was 
compromised in immune cell-specific Ppard knockout mice compared to wild type 
individuals, as was shown for experimental inflammatory bowel disease (Bassaganya-
Riera et al. 2011). Tanaka and colleagues were able to show that such observations, at 
least for the gut, may also be attributed in part to the direct PPARβ/δ target CD300a 
(Tanaka et al. 2014).  
2.2 Macrophages and their role in immunology 
Macrophages are myeloid cells that have first been described in 1863 (Slavjanski 
1866). They were recognized for their phagocytic activity by Élie Metchnikoff 
(Metchnikoff 1883; Metchnikoff 1887), who, by studying metazoan embryology, realized 
that phagocytosis is a fundamental function of tissue remodeling and wound healing. In 
his phagocytosis theory he later also advocated the phagocytes role in pathogen 
defense (Tauber 2003). Since Metchnikoffs insights at the end of the 19th century, the 
functions of macrophages have been investigated with great effort identifying, for 
example, their role in apoptosis (Reddien et al. 2001; Brown et al. 2002) and 
angiogenesis (Sunderkötter et al. 1994; Diez-Roux & Lang 1997). Nevertheless, 
macrophages remain best known for their essential role in immunity (Mackaness 1964; 
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Nathan 2012). Today, macrophages are often described as the gatekeepers of 
immunity. They patrol most tissues and exert their immunologic functions upon 
detection of pathogens. These are commonly described by a bipolar activation pattern 
with pathogen removal and Th1 activation on one side and suppression of inflammation 
through Th2 function on the other (Mills et al. 2000; Sica & Mantovani 2012). Currently 
this M1/M2 terminology is being reconsidered due to the diversity of macrophage 
activation and function (Martinez & Gordon 2014; Murray et al. 2014). This diversity is 
most likely due to microenvironmental features, e.g. growth factors and cytokines, 
which in turn can impact strongly on the immune response to the point of suppression 
or even reversal, as seen in autoimmunity or cancer (Crowther et al. 2001; Muñoz et al. 
2010; Jager et al. 2012). 
2.2.1 Macrophages in pathogen defense 
During acute infection, macrophages present the hosts first line of defense. As 
mentioned above, the tissue resident cells continuously screen their environment with 
an array of germline-encoded receptors (Taylor et al. 2005). Among these are 
receptors specific for pathogens called pattern recognition receptors (PRR) directed 
against common molecules displayed by pathogens, e.g. lipoteichoic acid, 
lipopolysaccharides (LPS), flagellin or double-stranded RNA. These conserved 
structures are referred to as pathogen-associated-molecular-patterns (PAMPs) and are 
used by innate immunity to discriminate self from nonself molecules and subsequently 
induce effector mechanisms, e.g. iron withdrawal, increased phagocytosis or secretion 
of cytokines and chemokines (Janeway & Medzhitov 2002; Gordon 2002; Recalcati et 
al. 2010). Moreover, macrophages may engulf pathogens or internalize their 
associated molecules to be processed and coupled to antigen presenting complexes. 
These in turn will be displayed on the surface of the antigen-presenting cell to activate 
effector cells of adaptive immunity (Sprent & Schaefer 1990; Sprent 1995). 
2.2.2 Macrophages of the tumor microenvironment 
The aforementioned surveillance receptors expressed by macrophages help to 
maintain the steady state in vivo. Changes in the environment are sensed and 
reactions to any stimuli are modulated in an orchestrated manner to ensure the 
balance between inflammation and tissue repair, thereby protecting the organism from 
damage to healthy tissue as well as abnormal growth, possibly leading to cancer (Shi 
et al. 2001; Shankaran 2001). Consequently, factors tilting this balance may lead to 
neoplastic growth (Coussens & Werb 2002). Infection alone is estimated to contribute 
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to every sixth neoplasm worldwide (Anand et al. 2008). It has become very clear over 
the past decades that the microenvironment contributes strongly to cancerous disease. 
Immune cells, especially macrophages, are therefore linking immunity and cancer. The 
special role of macrophages is underlined by their enormous repertoire of secretable 
factors (Crowther et al. 2001). These include angiogenic factors and chemoattractants 
that can impact strongly on surrounding cells (Sunderkötter et al. 1994; Schoppmann et 
al. 2002).  
Additionally, macrophages of the tumor microenvironment, often referred to as 
tumor-associated macrophages (TAMs), are linked closely to disease progression and 
outcome in various cancers (Bingle et al. 2002; Reinartz et al. 2014). A set of 
macrophage-secreted factors, e.g. vascular endothelial growth factor (VEGF), matrix-
metalloproteinases (MMPs) or epidermal growth factor (EGF) have been shown to 
directly impact on tumor progression and metastasis (Schoppmann et al. 2002; Pollard 
2004; Wyckoff et al. 2004). Yet, this complex interplay of environmental factors as well 
as autocrine and paracrine relations is difficult to grasp, particularly if the progression 
dependent nature of the TAM phenotype is taken into account. As outlined in a 2010 
review, TAMs implement various pro-tumorigenic traits at different stages of cancer 
development ranging from initiation to invasion and metastasis (Qian & Pollard 2010). 
TAMs may therefore be a promising therapeutic target in the struggle against cancer. 
Thus, great effort has been put into the exploration of a possible re-education of TAMs 
and the tumor microenvironment in order to obtain an anti-tumor phenotype in the last 
years (Hagemann et al. 2008; Topalian et al. 2012; Pyonteck et al. 2013; Jiang et al. 
2015). Ovarian cancer itself presents as an exceptional model for studies on tumor 
associated macrophages due to the fact of being frequently accompanied with 
peritoneal ascites. This malignant fluid accumulation often harbors large quantities of 
tumor and tumor-associated cells while at the same time giving insight into the actual 
microenvironment of these cells. 
2.3 Purpose and significance of this study 
The apparent interplay between lipid molecules, PPARβ/δ target genes, and immune 
regulation leads to the idea of this study. There are no sufficient studies addressing the 
role of PPARβ/δ in human macrophages despite the fact that the importance of this 
transcription factor in the context of immune regulation has been implied by murine 
studies (Lee et al. 2003; Kang et al. 2008; Odegaard et al. 2008). To obtain data that 
resembles the in vivo situation in humans appropriate genome wide approaches in 
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primary cells are necessary. This data will also establish reliable grounds for future 
investigation.  
In the light of disease, the influence of lipid sensors and their impact on immune 
regulation is also of particular interest. Since very little is known about the influence of 
lipids on macrophage function, there is desperate need to address this issue.  
This study is designed to investigate PPARβ/δs precise role in human 
macrophages identifying the regulated transcriptome in these cells. Thereby new 
insight into the functional implications will be obtained. Additional experiments in tumor-
associated macrophages will also demonstrate whether PPARβ/δ takes part in their 
specific phenotype. 
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3 Results 
3.1 The transcriptional PPARβ/δ network in human macrophages 
defines a unique agonist-induced activation state 
Till Adhikary*, Annika Wortmann*, Tim Schumann*, Florian Finkernagel*, Sonja 
Lieber, Katrin Roth, Phil ipp M. Toth, Wibke E. Diederich, Andrea Nist, Thorsten 
Stiewe, Lara Kleinesudeik, Silke Reinartz, Sabine Müller-Brüsselbach and Rolf 
Müller (2015) Nucleic Acids Research. 43(10): 5033–5051 DOI: 
10.1093/nar/gkv331 
* These authors contributed equally to the paper as first authors. 
 
To investigate the PPARβ/δ ligand regulated transcriptome in primary human 
macrophages, peripheral blood mononuclear cells were isolated from healthy 
volunteering adults by density gradient centrifugation followed by positive selection of 
adherent cells. The obtained cluster of differentiation (CD) 14 positive cells were 
differentiated to monocyte-derived macrophages (MDM) in RPMI1640 medium 
supplemented with 10% fetal calf serum (FCS). Surface staining for macrophage 
markers (CD32, CD64, CD86, CD206, HLA-DR) and intracellular CD68 analysis by 
flow cytometry on day three and five revealed the presence of macrophage markers 
(Figure S3). 
The transcript level of PPARD mRNA was assessed using reverse transcription 
quantitative polymerase chain reaction (RT-qPCR) at different time points during 
differentiation. A transcript level increase over time peaking around day five was seen 
(Figure 1A). The PPARβ/δ protein level, as assessed by western blot, was similarly 
rising over time showing the strongest signal around day six (Figure 1B, Figure S1). To 
verify functionality PPARβ/δ specific ligands were added to the cultured cells at 
different points. After one-day incubation the established target genes PDK4 transcript 
level was measured by RT-qPCR. The strongest ligand-inducibility compared to solvent 
was detected at day six post isolation (Figure 1C). Additionally chromatin 
immunoprecipitation (ChIP) showed localized enrichment of PPARβ/δ and RXR at the 
PDK4 enhancer. Re-ChIP experiments verified PPARβ/δ and RXR complex formation 
at the PDK4 enhancer region (Figure S2). Taken together, day six MDMs appear as 
very suitable model to explore the effects of PPARβ/δ ligands on macrophage 
differentiation and activation.  
Subsequent genome wide analysis using RNA- and ChIP- sequencing identified 
ligand regulated transcripts and PPARβ/δ as well as RXR enriched chromatin sites. In 
total 285 protein-coding putative direct target genes were upregulated by L165,041, a 
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PPARβ/δ specific agonist, while 388 were repressed. The inverse PPARβ/δ agonist 
treatment resulted in 246 downregulated genes and 174 genes with increased 
transcript frequency (Figure 2A and B, Table S2). A large number of genes showed 
inverse regulation by the ligands as opposed to the canonical concept. The increased 
transcript level of genes by inverse agonist and vice versa gave rise to the idea that an 
effect unrelated to PPARβ/δ might be responsible. However, data of bone marrow-
derived macrophages from Ppard null mice in comparison to wild type rejected this 
theory (Figure 2F). These genes were from here on classified as inverse target genes. 
ChIP-sequencing revealed 3798 and 32720 genes within 50 kb of enrichment 
sites for PPARβ/δ and RXR respectively (Figure 3A). 3502 genes were co-occupied 
and 66,4% of these showed enrichment specifically at transcription start sites, within 
introns or upstream locations (Figure 3C). Of the 285 L165,041 induced genes 132 
showed PPARβ/δ binding, the rest showed RXR binding. Among the solely RXR 
occupied genes we found angiopoietin-like 4 (ANGPTL4) a previously described 
canonical target gene (Mandard et al. 2004). Genes showing RXR binding in 
combination with L165,041-induction are therefore regarded to be canonical PPARβ/δ 
targets. 
The highest correlation of canonical target genes was found with lipid 
metabolism using Ingenuity Pathway Analysis (IPA) disease and function annotation 
(Figure 3E). Interestingly, other target genes were linked to cell motility or negatively 
correlated with systemic autoimmune disease. The aforementioned inverse PPARβ/δ 
targets, as analyzed by IPA upstream regulator analysis, were predominantly 
connected to cytokine signaling (Figure 4C). Subsequent functional annotation 
confirmed the link between PPARβ/δ in primary human macrophages and immune 
regulation (Figure 4F). Not surprisingly several immune regulatory genes were found 
among the inverse target genes, including chemokines, cytokines and members of the 
CD1 family (Table 1). 
To test for PPARβ/δ participation in immune regulation morphological changes 
in PPARβ/δ ligand treated MDMs were addressed. MDMs treated with respective 
ligand for six days during differentiation were Giemsa stained and analyzed. MDMs 
cultured in the presence of LPS or interleukin 4 (IL-4), initiating M1 and M2 polarization 
respectively, were used to judge similarity. Resemblance between L165,041 and IL-4 
treated MDMs was just as clear as between PT-S264, an inverse agonist, and LPS 
(Figure 6A-E, Figure S5A-F). A FITC-dextran uptake assay emphasized that the 
morphological resemblance between agonist and IL-4 treatment also correlated with an 
accompanying functional reduction in phagocytic/macropinocytotic activity (Figure 6F). 
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The reduction in the uptake as a result of agonist treatment was paralleled by a 
corresponding rise in T cell activation (Figure 7A). MDMs pretreated with CEFT-peptide 
in combination with L165,041 or solvent were co-cultured with autologous T cells. Their 
ability to present antigen and activate T cells, was assessed by flow cytometry, 
measuring the percentage of IFN-γ+, CD8+ cells. 
Evidence that PPARβ/δ agonists impact on macrophage phenotype was also 
given by experiments focusing on the protein products of inverse target genes CD274, 
CD32 and IDO1 (Figure 7C-H). All of these were readily reduced by agonist treatment 
including the supernatant concentration of the IDO1 enzyme product kynurenine.  
The functional annotation of L165,041 regulated genes predicted a positive effect 
on cell death of immune cells. We tested this in light of hypoxia as it resembles a stress 
situation commonly encountered by macrophages (Lewis et al. 1999). As figure 7I and 
supplementary figure 8 clearly show, PPARβ/δ agonists improve the viability while 
inverse agonists sensitize MDMs to hypoxic stress. 
At last we compared the datasets from MDMs treated with PPARβ/δ ligands to 
datasets of a human breast cancer (MDA-MB-231) and a myofibroblastic cell line 
(WPMY-1). The results point to cell type-specific functions of PPARβ/δ. While a small 
fraction of target genes with PPARβ/δ peaks are mutual (n=129) and related to energy 
homeostasis or lipid metabolism, none of the inverse target genes are shared by all 
three datasets. 
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3.2 Deregulation of PPARβ/δ target genes in tumor-associated 
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In order to learn more about the influence of PPARβ/δ in disease, focus was set on 
studying its role in TAMs of serous ovarian carcinoma (Schumann et al. 2015). These 
cells were isolated from malignant ascites by positive selection of CD14+ cells by 
means of magnetic cell sorting or adherent selection. TAMs kept in autologous ascites 
showed high transcript level of CD163 and low levels of MMP9 as compared to MDM 
cultures, which is consistent with their phenotype in vivo as we have described earlier 
(Reinartz et al. 2014) (Figure 1A). To address ligand responsiveness, TAMs and MDMs 
were treated with L165,041 or solvent for eight days in autologous ascites or cell 
culture medium respectively. As illustrated by figure 1B-E the morphological changes in 
response to PPARβ/δ agonist treatment was absent in TAMs while MDMs reacted as 
expected, and TAMs were non-responsive to exogenous agonist (Adhikary et al. 2015). 
To elucidate whether the TAMs’ lack in responsiveness is due to a deficiency in 
PPARβ/δ binding to chromatin, ChIP experiments were done. As presented for the 
PDK4 enhancer region monocytes, MDMs and TAMs collectively showed enrichment 
of RXR and PPARβ/δ, with approximately equal enrichment factors between MDMs 
and TAMs (Figure 2A). Subsequent comparative transcriptome analysis of TAMs and 
MDMs cultured in the presence of agonistic or inverse-agonistic ligand revealed that 
less than one third of agonist induced targets in MDMs was also upregulated in TAMs 
(Figure 2B). On the other hand, the number of inverse-agonist repressed genes in 
TAMs (50) was substantially larger compared to MDMs (18), hinting at the presence of 
agonistic ligands in TAMs.  
Validation of these findings by RT-qPCR for PDK4 and ANGPTL4 using MDMs 
and TAMs cultured in ascites or culture medium, correlated with the transcriptome 
data. Moreover culture conditions only had minor effect on TAM target gene induction, 
questioning the immediate influence of ascites (Figure 2D). Comparing the prior 
defined target genes (Table S3) in freshly isolated TAMs from 10 different patients and 
MDMs, using the obtained transcriptome data, demonstrated that a large fraction of 
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targets (54) had increased transcript levels in TAMs (Figure 3A) including about half of 
the genes upregulated in TAMs in vitro. Most of these genes not only showed higher 
expression in TAMs but also showed impaired induction by agonist (Figure 3C, Table 
1). These observations were confirmed by RT-qPCR analysis of three exemplary target 
genes in 12 MDM and TAM probes respectively (Figure 3D). Likewise PDK4 protein 
level in MDMs and TAMs cultured with and without L165,041, as illustrated by western 
blot, further supports the idea of deregulated and agonist insensitive PPARβ/δ target 
genes in TAMs (Figure 3E). In the case of ANGPTL4 this deregulation has direct 
implications for disease prognosis, as its secreted product is readily detectable in 
ovarian cancer patients’ ascites (Figure 3F). Moreover a strong negative correlation of 
the soluble ANGPTL4 level with relapse-free survival can be determined for serous 
ovarian cancer (Figure 3G). 
As a cause of the deregulation of PPARβ/δ targets, soluble agonists present in 
TAMs can be proposed. Culture of MDMs in the presence of malignancy-associated 
ascites followed by analysis of change in target gene transcription resulted in increased 
levels equivalent to L165,041 in some cases (Figure 5A). In the presence of ascites the 
agonist effect of L165,041 is strongly diminished (Figure 5B). This effect is clearly 
PPARβ/δ dependent as experiments with Ppard null mice compared to wild type 
animals show (Figure 5D). Here the induction of Pdk4 and Angptl4 by ascites is only 
present in wild type mice, which also show impaired agonist induction in the presence 
of ascites. The PPRE-dependence of the ascites-mediated target gene induction can 
also be seen in figure 5C. The three PPREs present in the enhancer region of 
PPARβ/δ target PDK4 were progressively mutated showing increasing reduction in 
ascites-mediated induction of transcript levels (Adhikary et al. 2015).  
In summation, these data strongly suggest the presence of endogenous 
agonistic ligands in the malignancy-associated ascites. Lipidomic analysis of 38 ascites 
samples by liquid chromatography–mass spectrometry/mass spectrometry (LC-
MS/MS) revealed high concentrations of polyunsaturated fatty acids (PUFAs) 
previously described to bind PPARβ/δ (Figure 6A, Table S6). Most prominent were 
linoleic acid (LA) with extremely high average concentrations (180µM), arachidonic acid 
(AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Evidently 
addition of LA, AA and DHA at a concentration of 20µM to the culture of MDMs resulted 
in upregulation of PDK4 (Figure 6B). As Figure 6C illustrates PDK4 transcript level 
rises dose-dependently upon LA concentration. The same holds true for the LA 
derivatives (9)Z, (11)E LA and (10)E, (12)Z LA. Compared to L165,041, LA exhibited 
comparable upregulation of PPARβ/δ targets in MDMs after 24h (Figure 6D). 
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Interestingly dose-dependent repression of PPARβ/δ targets by synthetic inverse-
agonists was still possible in MDMs cultured in ascites. As figure 6E shows the 
remedial influence of the inverse agonist PTS264 is especially strong for LRP5 and 
ANGPTL4 transcripts since a repression down to basal levels, compared to RPMI1640 
culture medium, can be achieved at concentrations around 2 µM (Figure 6E). 
Intriguingly, TAMs seem to stagnate in a deregulated state even if cultured in 
absence of ascites (Figure 2D). Fluorescent Nile Red staining of freshly isolated as well 
as four day cultured TAMs in presence and absence of serum however elucidated the 
cause for this apparent discrepancy. Freshly isolated TAMs were stained brightly red, 
displaying large quantities of intracellular lipid droplets which remained almost 
unchanged even if the cells were serum starved for four days (Figure 7A and B). The 
presence of lipid droplets was associated with impaired target gene upregulation by 
L165,041 (Figure 7C). MDMs cultured in the presence of LA, at concentrations 
resembling those of the ascites, readily accumulated lipid droplets (Figure 7D and E). 
These also remained stable over a period of four days which rendered PPARβ/δ target 
genes refractory to agonist-treatment despite serum starvation (Figure 7F). 
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4 Discussion 
4.1 The role of PPARβ/δ in human primary macrophages 
Despite various reports hinting at a role for PPARβ/δ in the context of immune 
regulation especially in macrophages no study has focused on this interplay. This 
report underlines the important role of this transcription factor in human macrophage 
function. 
The substantial increase in functional PPARβ/δ protein highlighting the 
significance of this factor in macrophage biology. In combination with the transcriptomic 
analyses performed, the insight into the complexity of PPARβ/δ transcriptional 
regulation in the context of human primary macrophages has been improved 
significantly. Additional to the prior known canonical target genes a new subgroup of 
regulated genes was identified that has apparent implications in immune regulation. 
Intriguingly, these targets were regulated solely in macrophages by agonistic ligands as 
shown by comparison with two distinct human cell lines. Further, a deviating concept of 
target gene regulation by PPARβ/δ emerged from the collected data. These inverse 
target genes are modulated by a different mechanism but also modulate in a cell type 
selective fashion. In case of primary macrophages mostly immune regulatory genes 
were modulated e.g. ARG2, BCL3, CCL24, CD1A, IDO1, IL10, PD-L1and TNF. 
The influence of PPARβ/δ selective ligands, as illustrated by the morphological 
changes in differentiating macrophages, point to a fundamental link between PPARβ/δ 
ligands and macrophage phenotype. In the light of biological relevance, functional 
consequences were addressed in this study and the results clearly underline the 
proposed connection. Special influence in T cell activation can be inferred from the 
data presented namely by the involvement of PD-L1, an inhibitory protein that engages 
the PD-1 receptor present on T cells, consequentially leading to impaired T cell 
activation (Freeman et al. 2000; Francisco et al. 2010). Likewise, IDO1 by means of 
kynurenine production in combination with L-tryptophan consumption is a potent 
inhibitor of the T cell response causing functional anergy in CD8+ T cells (Munn & 
Mellor 2013). Experimental data from macrophages treated with PPARβ/δ agonists 
concur as the result was an increase in CD8+ T cell activity. 
Furthermore, agonist treatment also increased the resilience of macrophages 
against hypoxic stress, which is often an accompanying factor of infection, tumor or 
wounds (Lewis et al. 1999). The significance of these implications in vivo, however, 
remains uncertain until further investigation. Nonetheless, these data validate the 
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paramount role for PPARβ/δ in macrophages and strongly underlines its contribution to 
immune modulation. 
4.2 PPARβ/δ in the light of disease 
In order to acquire further insight into the newly obtained role for PPARβ/δs impact on 
macrophage function in the light of disease, serous ovarian carcinoma was chosen as 
a model. Progression of this gynecological cancer is frequently related to the 
development of malignancy-associated ascites. This fluid accumulation often harbors 
vast amounts of tumor and tumor-associated cells and allows investigation of the tumor 
microenvironment. 
TAMs obtained from patients’ ascites showed the expected and previously 
described phenotype (Reinartz et al. 2014). Despite the presence of functional 
PPARβ/δ, these cells were non-responsive to ligands with respect to morphologic 
changes. Subsequent transcriptome analysis and further experiments revealed obvious 
differences between MDMs and TAMs. We established that a strong influence was 
caused by the microenvironment and went on to focus on ascites composition with 
special respect to ascites-borne PPARβ/δ ligands. Since PPARβ/δ is a known lipid 
sensor and activation leads to intracellular lipid accumulation (Vosper et al. 2001), 
binding fatty acids and derivatives thereof, lipidomic analyses were undertaken. The 
results of 38 ascites samples for 97 compounds confirmed the theory of ascites 
harboring substantial amounts of PPARβ/δ ligands. First and foremost polyunsaturated 
fatty acids stood out with extremely high concentrations, the highest of which was 
measured for linoleic acid, averaging at ~180 µM. Secondly, arachidonic acid and 
docosahexaenoic acid at average concentrations around 30 µ M were found. 
Noticeably, these concentrations far exceeded the determined range for sufficient 
PPARβ/δ binding (Xu et al. 1999). Moreover, these PUFAs were able to induce 
PPARβ/δ target genes in MDM cultures readily at a concentration of 20 µM . Most 
intriguing, LA in several cases reached the activation level achieved by synthetic 
ligand. Eicosapentaenoic acid and α-linolenic acid (ALA), which also have the 
propensity to bind PPARβ/δ as possible ligands had no significant effect on the 
transcript level of PPARβ/δ target PDK4, although the concentration used exceeded 
the detected level of EPA in ascites (ALA was not detected). The potential as agonistic 
ligand appears to be shared among the common ω-6 FA but does not extend to the 
ω-3 fraction of dietary FAs. 
When examining ex vivo TAMs large accumulation of lipid droplets emerged, 
thus providing an intracellular reservoir of accumulated lipids (Guijas et al. 2012). The 
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data of serum starved TAM and MDM cultures suggest this intracellular pool may 
provide previously stored endogenous ligands possibly for quite long periods, as a four 
day culture period only had minimal effects on the lipid stores and deregulated target 
gene levels. 
Interestingly, synthetic inverse agonists, such as PT-S264, were able to 
abrogate the effects seen with the ω-6 PUFAs in a dose-dependent manner. These 
ligands were able to restore the basal state of MDMs even in the presence of ascites. 
Inferring from these data, inverse agonist may be used to alleviate the effects of 
PUFAs on macrophages. This has exceptional implications as our previous study and 
functional annotations of PPARβ/δ targets showed their involvement in cell survival, 
cell migration and inflammation (Adhikary et al. 2015). The tumor microenvironment 
may therefore at least in part mitigate the phenotype observed for TAMs, which is 
associated with poor prognosis, exemplified in this study by the PPARβ/δ target 
ANGPTL4.  
To date, there are numerous reports stating the negative implications of de 
novo fatty acid synthesis in cancer (Kuhajda 2006). In the center of these reports is the 
fatty acid synthase, which is overexpressed in a variety of cancers. This enzyme allows 
mammals to synthesize FAs from acetyl- and malonyl-CoA, which in cancer is 
correlated with aggressive tumors, enhanced growth and survival. Consequently, this 
pathway is being pharmacologically targeted to improve outcome in cancer. Scarce 
effort has been put into elucidating the role of dietary fatty acids in this context. 
Several studies have earlier associated fatty acids with the clinical outcome of 
ovarian cancer (Tania et al. 2010). In the background of diet, it has been postulated 
that high levels of LA are correlated with higher membrane fluidity, enhanced cell 
motility and increased metastasis (Quinn 1983). A study has also shown that in ovarian 
cancer patients the percentage of LA in peripheral adipose tissue and omentum is 
decreased as result of FA mobilization from these sources (Yam et al. 1997). In 
combination with a report of controlled experiments performed on mice, advocating the 
negative influence of ω-6 FAs in a prostate cancer model, the implications are 
devastating (Berquin et al. 2007). Validation of this theory has already been proposed 
by an animal study demonstrating the negative influence of direct lipid transfer from 
adipocytes of the omentum to tumor cells (Nieman et al. 2011). As a result ovarian 
cancer metastasis and tumor growth were increased. 
This report clearly connects the tumor promoting phenotype of TAMs to the lipid 
composition of the tumor microenvironment, with special emphasis on PUFA level and 
composition. Although the presented data were obtained solely from ovarian cancer 
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patients, implications reach beyond this model, highlighting the importance of the fatty 
acid sensor PPARβ/δ not only in macrophage regulation but also in tumor biology. Yet, 
this work is only the basis for urgently needed further investigation elucidating the 
relation of lipid sensors and immune regulation in detail.  
Along this direction, our current investigations are addressing the molecular basis 
for FAs impacting on signaling pathways in human macrophages. Intriguingly we have 
observed that inverse regulation by PPARβ/δ affects to a large part STAT1 and NF-κB 
target genes. This places FAs at a central point in inflammation control and thereby 
cancer therapy. We hope to acquire detailed information on the interplay of PUFAs and 
macrophage function, hopefully leading to a better understanding and possibly an 
intervening strategy for cancer therapy. 
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